Hehlmann R, Lauseker M, Saussele S. et al. Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase. ASH 59th Annual Meeting & Exhibition, abstract 897.
Rituximab of obinutuzumab of plus CHOP bij nieuw-gediagnostiseerd DLBCL
aug 2017 | Lymfoom